HempFusion told investors that the preliminary findings are “validating and encouraging”
HempFusion Wellness Inc (TSE:CBD.U) (OTCQX:CBDHF) announced Tuesday that Validcare’s clinical study on CBD liver safety revealed no evidence of liver toxicity.
The industry-sponsored, decentralized human safety study of hemp derived CBD products was conducted with 839 participants and with the help of sector leaders like Denver-based HempFusion, which offers premium probiotic supplements and products containing CBD.
In a statement, HempFusion told investors that the preliminary findings are “validating and encouraging.”
READ: HempFusion Wellness to enter massive China market via subsidiary Probulin Probiotics on Alibaba Group Holding’s Tmall Global
“Participating in what is believed to be the largest human liver toxicology study on CBD was a tremendous honor, and the initial findings are incredibly validating for consumer safety,” HempFusion CEO Jason Mitchell said.
“We believe this is a pivotal step forward for the CBD industry, and we look forward to continuing to find ways to provide consumers with safe and quality products. When specifically looking at how our products performed in the study, having no liver toxicity only bolsters what we have always stated about our products. We believe they are safe.”
Dr Keith Aqua, one of the principal investigators in the study, said in a statement that the group is hopeful that the study will provide the US Food and Drug Administration (FDA) with enough data to help forge a regulatory path for hemp-derived CBD products.
“Due to the overwhelming success, we are adding a second cohort to this study to increase statistical certainty for liver safety and secondary measures across diverse populations and consumers with various medical conditions,” Aqua said.
Full safety results will be shared with participating brands and the FDA, according to Validcare’s CEO Patrick McCarthy.
“We understand the significance, importance and immediate need for CBD safety research for the FDA, industry and the US consumer,” McCarthy said. “This first of its kind, industry-led, multi-branded study required trust, collaboration, operational excellence, innovation, and resilience. It demonstrates the incredible potential for decentralized clinical research to increase participant access and accelerate results – even during the most challenging times.”
HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations.
Contact Angela at email@example.com
Follow her on Twitter @AHarmantas